Principal Investigator
Byron Lam
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231108
Clinical Trial Summary
A PHASE I/II STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE SUBRETINAL ADMINISTRATION OF SPVN06 GENE THERAPY IN SUBJECTS WITH ROD-CONE DYSTROPHY (RCD) DUE TO A MUTATION IN THE RHO, PDE6A, OR PDE6B GENE
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other